Sofosbuvir and ribavirin appear to better treat post-transplant cases of hepatitis C than the currently available therapies.

Sofosbuvir and ledipasvir plus either ribavirin or GS-9669 cured 100 percent of those with genotype 1 of hepatitis C with advanced liver disea...

Interim results of a Phase II study of the fixed-dose combo of sofosbuvir and ledipasvir have paved the way for a Phase III study of the hep C...

In 12 weeks, daclatasvir, asunaprevir and BMS-791325 cured 92 percent of treatment-naive people with genotypes 1a or 1b of hepatitis C virus

A 12-week regimen boasts high cure rates among those with the difficult-to-treat genotype 1 of the virus.

AbbVie’s interferon- and ribavirin-free combination therapy of ABT-450/r and ABT-267 cured 90 to 95 percent of people w/ genotype 1b of HCV

Gilead’s sofosbuvir boasted high cure rates when given in combination with ribavirin to those with genotype 2 or 3 of hepatitis C.

Sofosbuvir and ribavirin cured between 67 and 88 percent of those coinfected with HIV and genotypes 1, 2 or 3 of hepatitis C virus in a recent...

Simeprevir demonstrated greater efficacy than the current line of hepatitis C drugs among those with genotype and who had compensated liver d...

BMS has submitted for approval in Japan daclatasvir and asunaprevir as the world’s first interferon- and ribavirin-free hep C treatment.